Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2011 10:00 ET | Source: Active Biotech

Helén Tuvesson utsedd till forskningschef på Active Biotech

Dr. Helén Tuvesson tillträder tjänsten som forskningschef (Chief Scientific Officer) på Active Biotech den 1 april 2011. Helén Tuvesson kommer att rapportera till Tomas Leanderson, VD. Dr. Tuvesson...
March 15, 2011 10:00 ET | Source: Active Biotech

Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech

Dr. Helén Tuvesson takes up the post as Chief Scientific Officer within Active Biotech from April 1, 2011. Helén Tuvesson will be reporting to Tomas Leanderson, President & CEO. Dr. Tuvesson...
February 28, 2011 04:30 ET | Source: Active Biotech

Antal aktier och röster i Active Biotech

Antalet aktier och röster i Active Biotech har förändrats på grund av utnyttjande av personaloptioner samt den riktade nyemissionen till internationella institutionella investerare och kvalificerade...
February 28, 2011 04:30 ET | Source: Active Biotech

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options and the private placement with international institutional investors and qualified...
February 18, 2011 02:30 ET | Source: Active Biotech

Active Biotechs prostatacancerprojekt TASQ presenterat på 2011 Genitourinary Cancers Symposium

Lund den 18 februari, 2011 - Active Biotechs (NASDAQ OMX Nordic: ACTI) prostatacancer-projekt har presenterats på den vetenskapliga konferensen 2011 Genitourinary Cancers Symposium som hålls i...
February 18, 2011 02:30 ET | Source: Active Biotech

Active Biotech's TASQ prostate cancer project presented at 2011 Genitourinary Cancers Symposium

Lund, Sweden, February 18, 2011 - Active Biotech AB's (NASDAQ OMX Nordic:ACTI) prostate cancer trial has been presented at the scientific conference 2011 Genitourinary Cancers Symposium held February...
February 10, 2011 02:30 ET | Source: Active Biotech

Active Biotech AB Bokslutsrapport januari - december 2010

· Laquinimod - positiva resultat presenterade från ALLEGRO fas III-studie · TASQ - registreringsgrundande fas III-studie initieras Q1 2011 · ANYARA - pågående fas III-studie beräknas avslutas 2012...
February 10, 2011 02:30 ET | Source: Active Biotech

Active Biotech AB Year-end Report January - December 2010

· Laquinimod - positive results presented from ALLEGRO Phase III trial · TASQ - pivotal Phase III study initiated in the first quarter of 2011 · ANYARA - ongoing Phase III study expected to be...
January 27, 2011 02:00 ET | Source: Active Biotech

Active Biotech genomför riktad nyemission om 375 miljoner kronor

Active Biotech offentliggör idag att bolaget har genomfört en placering av 2.500.000 nya aktier, vilket tillför bolaget 375 miljoner kronor före emissionskostnader. Placeringen, som aviserades den 26...
January 27, 2011 02:00 ET | Source: Active Biotech

Active Biotech successfully completes private placement of SEK 375 million

Active Biotech today announces that it has completed a private placement of 2,500,000 new shares, providing the company with SEK 375 million before transaction costs. The private placement, which was...